Glucophage Provision In HR 2887 Could Be Breach Of Contract – Bristol
Executive Summary
A recent Supreme Court ruling related to the savings & loan industry bailout could serve as a precedent for legal challenges by Bristol-Myers Squibb to the Glucophage provision in the pediatric exclusivity reauthorization legislation
You may also be interested in...
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
Pediatric Bills' Generic Approval "Carve-Out" Needs Refinement, Hatch Says
Provisions of bills to renew the pediatric exclusivity program which allow for approval of generics despite protected labeling by innovators should be revised, Sen. Orrin Hatch (R-Utah) said.